Court reinstates Pfizer whistleblower suit

A Pfizer whistleblower will get his day in court. Dr. Peter Rost (photo) accused the company of illegally marketing Genotropin, a human growth hormone product; he filed suit after he lost his job (he was a VP at Pharmacia when Pfizer bought the company). Info in Rost's suit led to a $34.7 million fine against Pfizer, but a federal district court threw out his complaint.

Now, the U.S. Court of Appeals has overruled the lower court. The suit will be reinstated, and Rost will have a chance to amend it. The upshot? Rost may get a share of that $34.7 million fine, and Pfizer may be vulnerable to additional fines. The drugmaker said in a statement that it's confident it will prevail--and emphasized that it was Pharmacia that promoted Genotropin for youth, beauty, and athletic prowess.

- check out Pfizer's statement at Rost's blog
- read this Pharmalot item

Related Articles:
Pfizer leaves exec dangling. Report
Grassley: Whistleblowers, call me. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.